Evaluation of diclofenac utilization patterns before and after digital risk minimization intervention in outpatient settings in Montenegro
ConclusionsAlthough a significant decrease in diclofenac prescription in both cohorts occurred, diclofenac is still prescribed, even in diagnoses contraindicated for its use. Further improvements of existing tools and the creation of new ones are necessary for minimization of cardiovascular and other risks related to diclofenac. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - February 24, 2024 Category: Drugs & Pharmacology Source Type: research
Efanesoctocog alfa in hemophilia A: a profile of its use
AbstractEfanesoctocog alfa [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; ALTUVIIIO®], indicated for routine prophylaxis, on-demand treatment of bleeding episodes, and perioperative management of bleeding, is a useful addition to the therapies available for the management of hemophilia A in adults and children. Its half-life is three- to four-fold longer than existing (standard and extended half-life) factor VIII replacement products, which enables once-weekly administration. In a phase 3 trial, pretreated adolescents and adults (aged ≥ 12 years) receiving efanesoctocog alfa prophylaxis had a l...
Source: Drugs and Therapy Perspectives - February 24, 2024 Category: Drugs & Pharmacology Source Type: research
Treat borderline personality disorder with psychotherapy and concomitant psychiatric disorders with adjuvant pharmacotherapy
AbstractNo class of medications has consistently improved symptoms of borderline personality disorder (BPD) in randomized clinical trials, and no pharmacological treatment has been approved specifically for BPD. Psychotherapy is the treatment of first choice in BPD, and the general consensus is that pharmacotherapy should be used mainly for the treatment of comorbid disorders. However, most patients with BPD are medicated even when they do not have comorbidities. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - February 24, 2024 Category: Drugs & Pharmacology Source Type: research
Expand the treatment horizon of premenstrual dysphoric disorder with targeted therapeutic approaches
AbstractPremenstrual dysphoric disorder (PMDD) is a sex-specific cyclic mood disorder characterized by heterogenous mood and physical symptoms during the luteal phase of the menstrual cycle. Currently available treatment options for PMDD are limited and suboptimal. With advanced understanding in pathophysiology of PMDD, the interaction between the gamma-aminobutyric acid (GABA) system and allopregnanolone, a neuroactive steroid derivative of progesterone, have been proposed as a potentially effective target for the treatment of PMDD. Although further research is needed, early clinical findings of new targeted treatments, s...
Source: Drugs and Therapy Perspectives - February 24, 2024 Category: Drugs & Pharmacology Source Type: research
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use
AbstractPirtobrutinib (Jaypirca®), an oral, small molecule, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, is a promising new treatment option for patients with relapsed or refractory mantle cell lymphoma (MCL), including those who have received a BTK inhibitor. In the multicentre, open-label, phase 1/2 BRUIN trial, pirtobrutinib demonstrated meaningful response rates and durable efficacy in patients with heavily pretreated (including with a covalent BTK inhibitor) relapsed or refractory MCL. Pirtobrutinib had a manageable tolerability profile, with most treatment-related adverse events being mild to mo...
Source: Drugs and Therapy Perspectives - January 27, 2024 Category: Drugs & Pharmacology Source Type: research
Preferably pre-empt pathological scars, or pick from a plethora of therapies
AbstractPathological scars, including keloids and hypertrophic scars, are best managed by preventative strategies, such as occlusive silicone dressings or gels, or pressure therapies. For established lesions, intralesional corticosteroids, particularly triamcinolone acetonide (TAC) are first-line therapies. Combining TAC with intralesional 5-fluorouracil or non-pharmacological options such as lasers is generally more effective than monotherapy and may be better tolerated. Other treatments include cryotherapy, botulinum toxin type A, and more novel therapies including anti-cancer and anti-inflammatory agents. Well-designed ...
Source: Drugs and Therapy Perspectives - January 8, 2024 Category: Drugs & Pharmacology Source Type: research
Correction to: Tezepelumab in severe asthma: a profile of its use
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - January 5, 2024 Category: Drugs & Pharmacology Source Type: research
Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use
AbstractNirsevimab (Beyfortus ™), a long-acting monoclonal antibody targeting the respiratory syncytial virus (RSV) fusion (F) protein, is the first prophylactic monoclonal antibody against RSV to be licensed for use in all infants in their first RSV season, and thus presents a highly valuable tool in the fight against RSV dis ease in children. Additionally, in the USA and Canada, nirsevimab is licensed for use in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Data from randomized, double-blind, placebo-controlled clinical trials show that a single intramuscul...
Source: Drugs and Therapy Perspectives - December 22, 2023 Category: Drugs & Pharmacology Source Type: research
The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients
ConclusionOverall, PH FDC SC demonstrated potential economic and organizational advantages for hospitals and patients compared with P+T IV, even though patients treated subcutaneously experienced longer waits between activities, indicating the need for optimized organizational choices. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - December 21, 2023 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to Referees
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - December 20, 2023 Category: Drugs & Pharmacology Source Type: research
Understand the benefits and risks of intravenous methadone for perioperative and chronic cancer pain management
AbstractIntravenous (IV) methadone is a long-acting analgesic opioid with unique properties that may be useful in the management of acute perioperative and chronic cancer pain. Several randomized clinical trials have demonstrated that intraoperative IV methadone is effective for perioperative pain and reduces the use of postoperative opioids. Limited evidence shows that IV methadone is promising for chronic cancer pain; however, further studies are required. Methadone is associated with opioid-related adverse effects, with particular safety concerns around the risk of prolonged respiratory depression and QT interval; caref...
Source: Drugs and Therapy Perspectives - December 13, 2023 Category: Drugs & Pharmacology Source Type: research
Tezepelumab in severe asthma: a profile of its use
AbstractTezepelumab (tezepelumab-ekko; TEZSPIRE®), a first-in-class monoclonal antibody targeting thymic stromal lymphopoietin, represents a novel, effective and generally well tolerated treatment option for patients with severe asthma across a wide range of phenotypes. In randomized, double-blind, phase 2 (PATHWAY) and phase 3 (NAVIGATOR) trials, subcutaneous tezepelumab demonstrated a significant reduction in annualized asthma exacerbation rate among patients with severe uncontrolled asthma. The efficacy was seen across a broad range of patients with different asthma endotypes and phenotypes, including eosinophilic and ...
Source: Drugs and Therapy Perspectives - December 7, 2023 Category: Drugs & Pharmacology Source Type: research
Spesolimab in generalised pustular psoriasis flares: a profile of its use
AbstractSpesolimab (Spevigo®) is a promising new treatment for generalised pustular psoriasis (GPP) flares. GPP is a rare and life-threatening autoinflammatory disease characterized by flares of widespread skin lesions with pustules, which may be accompanied by systemic inflammation. Spesolimab, a novel interleukin (IL)-36 receptor antagonist, is approved in the EU and USA for the treatment of GPP flares in adults. In a pivotal phase 2 trial, a significantly higher proportion of patients with a GPP flare who received a single intravenous dose of spesolimab had no visible pustules and clear or almost clear skin at the end ...
Source: Drugs and Therapy Perspectives - December 2, 2023 Category: Drugs & Pharmacology Source Type: research
Manage vitiligo with a personalised approach: consider old and new treatments
AbstractVitiligo is an autoimmune condition that causes loss of skin colour. For many years it has been managed using treatments that simply dampen immune and inflammatory responses, including topical corticosteroids and calcineurin inhibitors, oral corticosteroids and phototherapy. Ongoing research, however, is helping to uncover what drives the development of vitiligo and identify potential new treatment targets. The Janus kinase (JAK)/signal transducer and activator of transcription signalling pathway has been identified as playing an important role in vitiligo, leading to the approval of the first US FDA-approved treat...
Source: Drugs and Therapy Perspectives - November 24, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: RBX2660 (REBYOTA ®) in preventing recurrence of Clostridioides difficile infection: a profile of its use in the USA
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 24, 2023 Category: Drugs & Pharmacology Source Type: research
